Cancer Vaccines: Targeting Cancer Genes for Immunotherapy – – A Conference by Keystone Symposia on Molecular and Cellular Biology – Late publishing
Reporter: Aviva Lev-Ari, PhD, RN
Though the Conference took place in March 6—10, 2016, I am posting its Agenda on 7/4/2016.
It was 4/3/2016 when we launched “DrugDiscovery @LPBI Group” with a focus on Cancer Vaccines: Targeting Cancer Genes for Immunotherapy. The academic nature of this conference is of particular interest to our Team at present time while the Team is working on Biologics for Pancreatic Cancer: New MOA in Immunotherapy.
In addition, of interest are the following two resources:
Three Methods for Design of a Novel Immune Therapy for Cancer: Conceptual Foundation for Development of a Novel Mechanism of Action for a Combination Therapy of Biologics
Curator: Aviva Lev-Ari, PhD, RN
and
Pancreatic Cancer: Articles of Note @PharmaceuticalIntelligence.com
Curator: Aviva Lev-Ari, PhD, RN
Keystone Symposia on Molecular and Cellular Biology: Mission
Keystone Symposia will serve as a catalyst for the advancement of biomedical and life sciences by connecting scientists within and across disciplines at conferences and workshops held at venues that create an environment conducive to information exchange, generation of new ideas and acceleration of applications that benefit society.
Background
Keystone Symposia on Molecular and Cellular Biology is a 501(c)(3) nonprofit organization headquartered in Silverthorne, Colorado, USA that convenes open, peer-reviewed conferences across a broad range of the life sciences. Approximately 50-60 conferences take place each year. More than half the symposia are held in mountain venues across the American and Canadian West, with the remainder in generally North American cities and various global locations. We have now convened conferences on six continents: Africa, Asia, Australia, Europe, North America and South America.
Scientific content for each conference is organized by volunteer scientists who are experts in their respective fields and who also select program speakers, with guidelines from Keystone Symposia to encourage fresh and diverse participation. The conferences are typically three to four full days in length and consist of two daily plenary sessions complemented by workshops and poster sessions. The meeting format is designed to maximize informal networking among participants. Scholarships and travel awards help make possible the participation of graduate students and postdoctoral fellows, who typically account for 40% of attendees each year. Keystone Symposia has a range of Diversity in Life Science Programs and actively encourages participation of underrepresented investigators and scientists from developing countries.
Keystone Symposia’s Chief Executive Officer reports to the Board of Directors and, along with the Chief Scientific Officer, acts on the advice of a Scientific Advisory Board comprised of more than 75 leading scientists from academia, industry and government worldwide. This Board meets twice a year to determine conference topics, identify potential scientific organizers and review proposed programs.
We receive revenue from two sources: registration fees (approximately 65-70%) and generous support from corporations, foundations, government entities and individuals (approximately 30-35%). This support provides funding for scholarships as well as speaker travel expenses (no honoraria are paid), allowing registration fees to be kept as low as possible.
A staff of 40 full-time, part-time or seasonal employees handles all aspects of administration, meeting management/logistics, attendee services, fundraising and marketing.
History
Founded in 1972 in Los Angeles as the ICN-UCLA Symposium on Molecular Biology by Professor C. Fred Fox, the organization evolved into UCLA Symposia before relocating to Silverthorne, Colorado in 1990. At that time we became a free-standing division of a nonprofit called The Keystone Center and were renamed Keystone Symposia on Molecular and Cellular Biology. We separated from The Keystone Center and became an entirely independent nonprofit in a phased transition beginning in 1995 and ending in 1997.
The first meeting organized was on Membrane Research in Squaw Valley, California in March 1972. While still known as UCLA Symposia, the organization convened the first-ever open, international meeting on AIDS in 1984, which was widely credited with catalyzing a consensus that AIDS was caused by a retrovirus now known as the Human Immunodeficiency Virus.
We proudly celebrated our 40th anniversary in 2012!
Timeline of Key Milestones
1972: Keystone Symposia was founded as the ICN-UCLA Symposium on Molecular Biology and held an initial conference on membrane research in Squaw Valley, California, March 13-17, 1972.
1990: Keystone Symposia relocated to Silverthorne, Colorado, became a division of The Keystone Center and was renamed Keystone Symposia on Molecular and Cellular Biology.
1995-97: Keystone Symposia became an independent 501(c)(3) nonprofit organization.
2001: First conference outside of the US in Canada (“Hematopoiesis” in Whistler, British Columbia, Canada).
2005: First conference in Asia (“Stem Cells, Senescence and Cancer” in Singapore).
2006: First conference in Europe (“Multi-Protein Complexes Involved in Cell Regulation” in Cambridge, UK).
2007: First conference in Africa (“Challenges of Global Vaccine Development” in Cape Town, South Africa).
2009: First conference in Australia (“Telomere Biology and DNA Repair” in Ashmore).
2013: First conference in South America (“The Innate Immune Response in the Pathogenesis of Infectious Disease” in Ouro Preto, Brazil).
The past decade has seen tremendous developments in novel cancer therapies, through targeting of tumor cell-intrinsic pathways whose activity is linked to genetic alterations, as well as the targeting of tumor cell-extrinsic factors such as growth factors. Remarkable clinical success of checkpoint inhibitors as well as adoptively transferred genetically engineered T cells further demonstrates the critical role of T cells in cancer control and rejection. However, many patients still do not respond to checkpoint inhibitor therapies, possibly due to the lack of T cell repertoire with specificity against cancer antigens. This creates the need for effective means of expanding the T cells in patients via immunization, i.e., cancer vaccines. Much progress has been made in recent years in this regard, and several phase III clinical trials testing various approaches to therapeutic vaccination are ongoing. The challenge for next-generation vaccines is to resolve the discrepancy between the immune and clinical efficacy measured by the rate of cancer rejection. The future immunotherapy of cancer lies in combination approaches targeting T cells as well as cancer genes to combat underlying inflammation. Spectacular progress has been made in these two parallel fields, i.e., cancer genomics and genetics, and tumor immunology. It is time now to link these fields to enable the linking of genetic alterations with the type of immune response. The meeting will therefore host cancer geneticists, cancer biologists, experts in cancer antigen presentation, tumor immunologists and vaccinologists. It will discuss the immunological basis for therapeutic cancer vaccines and how the current understanding of cancer genomics, antigen presentation and T cell biology might enable development of next-generation curative therapies for patients with cancer.
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, March 6 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 10 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 11 in order to fully experience the meeting.
SUNDAY, MARCH 6
MONDAY, MARCH 7
Visualizing and Deconstructing Immune Responses in situ
Regulation of Antigen Cross Presentation and Anti Tumor Immune Responses
Reengineering the Tumor Microenvironment to Enhance Cancer Treatment: Bench to Bedside
Protein Engineering Approaches to New Biologicals
Synergy of Therapeutic Vaccination against HPV16 Oncogenic Proteins and Standard Chemotherapeutics
Phosphopeptides Displayed by MHC Molecules as New-Generation Cancer Vaccine Targets
Micro Needle Technologies for Intratumoral Drug Delivery and Combination Screening
PK/PD Modeling for Macromolecular Drug Delivery
Short Talk: Noninvasive Detection of Tumor-Infiltrating Lymphocytes using Anti-CD8 Immuno-PET: Impact of Protein Dose
Combined CD27-Costimulation and PD-1-Inhibition Recapitulates CD4+ T-cell Help in Therapeutic Vaccination Against Cancer
Combination Immunotherapy: T-cell Costimulation (OX40L, TL1A, 4-1BBL and ICOSL) Secreted Locally by Gp96-Ig Vaccines, Elicits Robust Antigen-Specific, Memory T Cell Responses and Tumor Elimination
Development of Tools to Evaluate Anti-tumor Immunity
Nanodisc-Based Peptide Vaccines for Personalized Cancer Immunotherapy
Self-Assembling Nanoparticles Codelivering Peptide Neoantigens and TLR-7/8 Agonists Enhance the Breadth and Potency of Anti-Tumor Immunity
Utilizing Protein Carriers to Engineer Cancer Vaccines with Improved Potency
Targeting Antigen to Human CD141+ Dendritic Cells via CLEC9A in vitro and in vivo Confers Effective Cross-Presentation to CD8+ T Cells
Synergy Generates Picomolar Potency and a High Resistance Barrier in Combinectin, a Novel Trispecific HIV-1 Entry Inhibitor with Clinical Promise
Characterizing the Preclinical Candidate, NI-1701, a CD47 Targeting Bispecific Antibody in Development for the Treatment of B Cell Lymphomas and Leukemias
MGD009, a B7-H3 x CD3 Bispecific Dual-Affinity Re-Targeting (DART®) Molecule Directing T Cells to Solid Tumors
Donor-Derived B Cells Produce Potent AML-Specific Antibodies that Recognize a Novel Tumor-Specific Antigen and Mediate Graft-Versus- Leukemia Immunity
Targeting Immunomodulators to Lymphocytes Via Amphiphilic Gold Nanocarriers
Antibody-based Control of CAR-T Cell Therapy
Regulation of Antigen Cross-presentation in Dendritic Cells
Dendritic Cells as Cancer Vaccines
T Cell-Antigen Presenting Dynamics in the Tumor Microenvironment
Short Talk: Radio-resistant Stromal Cells Initiate the Innate Response to Cyclic Dinucleotides
Evolution of Antibodies for Optimized Effector Function Activities
IgA as Alternative Therapeutic Antibody: Combination with IgG, Half-Life Extension and More
De novo Design of Novel Protein Functions
Functional Aspects of Antigen- and Fc-Dependent IgG Hexamer Formation
TUESDAY, MARCH 8
Impaired Induction of High-Quality Effector CD8+ T-Cells in Old Humans
Generation of Long-Lived Cancer Antigen-Specific CD8+ T Cell Memory
Novel Subsets Involved in T Cell Anti-Tumor Immunity
Exploiting Antiviral Immune Mechanisms for Cancer Immunotherapy
Short Talk: Cyclin Dependent Kinase 5 (CDK5) Controls PD-L1 Expression via Phosphorylation of IRF2BP2 in Murine Medulloblastoma and CDK5 Deficiency Results in CD4+ Dependent T-Cell Rejection
Short Talk: Glycogen Synthase Kinase 3 Inhibition Blocks PD-1 Expression via Increased Tbet Expression for Enhanced CD8+ Cytolytic T-Cell Responses
Systematic Characterization and Comparative Analysis of Antibody Repertoires
EMBO Young Investigator Lecture: Regulation of Antibody Responses by B Cell Mechanical Activity
Rapid and Large-Scale Isolation of Potent Neutralizing Antibodies from a Survivor of the 2014 Ebola Virus Outbreak
Short Talk: Unanticipated Global Changes in IgG1 from Mutation of FcRn Binding Site Residues
Short Talk: Correlations of Antibody Response Phenotype to Genotype Revealed by Molecular Amplification Fingerprinting
Dissecting Cross-Presentation in Dendritic Cells: Who, How and Why?
INT230-6 Administered Intratumorally Converts Tumor to an Endogenous Vaccine in Mouse Colon Cancer
Creation of Biological Microparticles from Mesenchymal Stem Cell (MSC) to Deliver Vaccines and other Therapeutics such as Proteins or Nucleic Acids
Activation of the Cytosolic RNA Receptor RIG-I in Tumor and Immune Cells Triggers Efficient Anti-Tumor Immunity and Synergizes with Checkpoint Blockade
Combination Immunotherapy of an Autochthonous Murine Lung Cancer Model Expressing Human CEA as a Tumor-Associated Self-Antigen
Vaccines Facilitating Cross-Presentation for the Induction of Tumor-Immunity Overcoming Tumor Induced Suppression
Various forms of CD40L Encoded as an Immune Plasmid Adjuvant Generate Unique Anti-HPV DNA Vaccine Induced Responses
Features of Memory CD8+ T Cells in Chronic Infection
Lineage Relationship of Effector and Memory T Cells
Targeting Immunometabolism as a Means of Enhancing Immunotherapy
Short Talk: Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for TCR and CAR based Adoptive Immunotherapy of Cancer
Drugging Intracellular Targets with Vaccines and Human Therapeutic TCR Mimic Antibodies
Antibody Drug Conjugates for Cancer Therapy
Multispecific Antibody Therapeutics Derived from Systems Biology and Computational Modeling
Functionalization of MAbs Using Mechanical Bonds
WEDNESDAY, MARCH 9
Molecular Mechanisms of Cancer Antigen Presentation at the Tumor Site
Insights from Listeria monocytogenes for the Development of Vector- and Small Molecule-Based Cancer Immunotherapy Strategies
Advances in Oncolytic Virus Immunotherapy
In situ Vaccination by Radiation Therapy
Short Talk: Overcoming Immune Regulation to Kill Cancers: ImmTAC Targeting and Checkpoint Inhibition
Detecting Tumor and Immune Cell Responses to Therapy Using ImmunoPET
Antibody-Based Radiotherapy and Radiodetection of Cancer
Tumor Paint and Penetrating Peptide Drug Conjugates
Short Talk: Utilizing Prosthetic Antigen Receptors (PARs) for Anti-EpCAM Cell-directed Immunotherapy
Short Talk: Antibody Based Switches Control the Activation and Targeting of CAR T Cells for B Cell Malignancies
Novel Invariant Natural Killer T Cell-Based Immunotherapies for Cancer
Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis
Targeted Adenoviral Delivery of Protein-Based Therapeutics to the Tumor Microenvironment
Major Histocompatibility Class I – Antibody Fusion Proteins (pMHCI-IgGs) that Link B16 Melanoma Cells to Cytomegalovirus-Specific CD8 T Cells Control B16 Melanoma in vivo
Divergent Sequences Stabilize Similar Antigen-Binding Conformations in the Affinity Maturation of a Broadly Neutralizing Influenza Antibody Lineage
Statistical Design for Effector Function Engineering of Hexameric Fc Domains
Glycan: A Sweet Opportunity for Antibody Discovery
Antitumor Activity of Immunomodulatory Antibodies
PD-1 Blockade in Cancer Therapy: Mechanism-Based Biomarkers and New Frontiers
CD96/TIGIT/DNAM Pathway and Tumor Rejection
THURSDAY, MARCH 10
Harnessing Host Response to Premalignancy in Prevention of Cancer
Dendritic Cell Based Cancer Immunotherapy
The Mechanistic Basis of Cancer Immunotherapy
Modulation of Innate Immunity in Cancer
Short Talk: Eradication of Large Established Tumors by Combination Immunotherapy Engaging Innate and Adaptive Immunity
Short Talk: Improved Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Abs by Selective FcgammaR-Engagement
MuPeXI: A Tool for Prediction of Neo-Epitopes from Tumor Sequencing Data
UV1 – A Second-Generation, Peptide-Based, Therapeutic Cancer Vaccine (TCV) Targeting the Reverse Transcriptase Subunit of Human Telomerase (hTERT
Tumor-Specific Mutant Antigens in Cancer Immunotherapy
Safety Assessment of DNA Methyl Transferase Inhibitors in Combination with NY-ESO T-cell Therapy.
Optimization of Extracellular Vesicle Labels for NanoFACS
Novel and Shared Neoantigen for Glioma T Cell Therapy Derived from Histone 3 Variant H3.3 K27M Mutation
Tumor Mutant Antigen-Specific CD8+ T-cells Require CD4+ T-cell Help to Induce Tumor Regression
CMV-induced MHC-II and MHC-E-Restricted CD8+ T Cells: A Role in Cancer Immunotherapy
Genomics of Human Immune Response
Cancer-Specific Mutations as Tumor Rejection Antigens
Targeting Tumor Neoantigens: Developing Personalized Cancer Vaccines
Intracellular Antibody Immunity and the Cytosolic Fc Receptor TRIM21
Antibody-like Properties and Functions of Antiviral Carbohydrate Binding Proteins
FRIDAY, MARCH 11
Keystone Symposia thanks our Sponsor for generously supporting this meeting:
 |
We gratefully acknowledge support for this conference from:
These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.
Click here to view all of the donors who support the Directors’ Fund.
We gratefully acknowledge additional support for this conference from:
 |
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
| If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Assistant Director of Development, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: |
SOURCE
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aptubman
Arav Gandhi
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22
Leave a Reply